Eric K. Singhi, Thoracic Medical Oncologist and Assistant Professor at the MD Anderson Cancer Center, recently shared a post on X/Twitter:
“Neoadjuvant, adjuvant, or both? Patrick Forde discusses the nuanced choices thoracic medical oncologists and patients with early-stage Non-small-cell lung cancer (NSCLC) are facing in clinics today.”
Source: Eric K. Singhi/X